Program
tegoprazan
Also written as “Tegoprazan”, “Tegoprazan 50 mg” and “BLI5100”.
Its studies are mostly in Esophagitis · Non-Erosive Reflux Disease · Gastroesophageal Reflux · Peptic Ulcer · Duodenal Ulcer, led by 4 companies.
Drug pageTegoprazan: every studyAll 62 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HK inno.Nits history only | 376 open or running | phase 4since Mar 13, 2020 | Nov 14, 2011 | Jan 31, 2027phase 1 · NCT07853248 |
| Shandong Luoxin Pharmaceutical Group Stockits history only | 70 open or running | phase 3since Jul 9, 2018 | Jan 25, 2018 | none ahead |
| Sebela Pharmaceuticalsits history only | 30 open or running | phase 3since Oct 17, 2022 | Oct 17, 2022 | none ahead |
| Carnot Laboratories | 11 open or running | phase 4since May 20, 2025 | May 20, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Carnot Laboratories only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named tegoprazanINNProposed as its International Nonproprietary Name in WHO's List 113 · before, BLI5100
- May 20, 2025First study: phase 4 study in Gastroesophageal RefluxFirst studyNCT06991348 · 128 planned · Mexico
TargetBeta
“Potassium-transporting ATPase blocker”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
The one study Carnot Laboratories leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06991348Gastroesophageal Reflux · Mexico | 4 | Recruiting | Nov 30, 2025 | 128 |
How it is read
Names in the registry
- “Tegoprazan”, 10 entries
- “Tegoprazan 50 mg”, 5 entries
- “BLI5100”, 3 entries
- “Tegoprazan 50mg”, 3 entries
- “CJ-12420 50mg”, 3 entries
Conditions, from the studies’ own filings
- Esophagitis, 6 studies
- Non-Erosive Reflux Disease, 4 studies
- Gastroesophageal Reflux, 4 studies
- Peptic Ulcer, 1 study
- Duodenal Ulcer, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.